Cellectis raises $228.3M, lists in U.S.

Immunotherapy company Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) lost $2.20 to $39.30 in its first day of trading on NASDAQ on Wednesday after raising $228.3 million through the sale of 5.5 million American Depositary Shares (ADSs) at $41.50. Last month, the company filed to raise up to $115 million in the financing; the company then amended the offering, indicating that it planned to sell 3.5 million ADSs.

BofA Merrill Lynch; Jefferies; Piper Jaffray; Oppenheimer; and Trout Capital are underwriters. The company has been listed since 2007 on Euronext, where the stock lost EUR 3.60 to EUR 36.40 on the day. ...